ArticleNature2022
T cells specific for α-myosin drive immunotherapy-related myocarditis.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 241 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
241citing papers in PubMed, 6 pooled it
27.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
241 citing papers in PubMed, 6 syntheses or guidelines pooled it, 289 citations in OpenAlex.
- Troponin for surveillance of immune checkpoint inhibitor-associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Immune checkpoint inhibitor-related myositis, myocarditis, and myasthenia gravis overlap syndrome: a systematic review and pooled analysis of individual cases.Frontiers in immunology · 2026Pooled it
- Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis.Journal of translational medicine · 2025Pooled it
- The Cardiotoxicity Risk of Immune Checkpoint Inhibitors Compared with Chemotherapy: A Systematic Review and Meta-analysis of Observational Studies.Cardiovascular toxicology · 2025Pooled it
- Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients.Journal of neurology · 2024Pooled it
- Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.Nature medicine · 2023Pooled it
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Interpretable AI model reveals spatial codes of cell recruitment in tissues.Nature biomedical engineering · 2026Article
- Heart-specific T cell responses: from antigens to disease mechanisms.Nature reviews. Cardiology · 2026Review
- Cytomegalovirus Latency Fuels Inflammation Following Myocardial Infarction.Circulation research · 2026Article
- [Myositis induced by immune checkpoint inhibitor therapy].Zeitschrift fur Rheumatologie · 2026Review
- Blocking PD1 prevents T-cell-promoted fibrosis in myocardial infarction.Cell discovery · 2026Article
- Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference.Journal of the American Society of Nephrology : JASN · 2026Article
- The Cardio-Onco-Immune Axis: immunopathological mechanisms in the cardiac microenvironment of checkpoint inhibitor-induced myocarditis.Acta pharmacologica Sinica · 2026Review
- Review
- Review
- Generation of three induced pluripotent stem cell lines from an immune checkpoint inhibitor-induced myocarditis patient and controls.Stem cell research · 2026Article
- A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.Journal of thoracic disease · 2026Review
- Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis.Science advances · 2026Article
- Cardio-Oncology in Cold Climates: Epidemiological Features, Bidirectional Interaction Mechanisms, and Integrated Management Strategies.Cardiovascular toxicology · 2026Review
181 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors at 6 institutions in 3 countries.
Margaret L AxelrodDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-4713-8798
Wouter C MeijersDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Elles M ScreeverDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Juan QinDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-0821-6290
Mary Grace CarrollDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Xiaopeng SunDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Elie TannousDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Yueli ZhangDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Ayaka SugiuraDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-5326-5019
Brandie C TaylorDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Ann HannaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Shaoyi ZhangSection of Cardio-Oncology and Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8248-9481
Kaushik AmancherlaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Warren TaiDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-9355-7198
Jordan J WrightDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-2043-0150
Spencer C WeiDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Susan R OpalenikDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Abigail L TorenDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Jeffrey C RathmellDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-4106-3396
P Brent FerrellDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-1140-9154
Elizabeth J PhillipsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-7623-3383
Simon MallalDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-6390-773X
James P AllisonDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Javid J MoslehiDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Javid.Moslehi@ucsf.edu.
Justin M BalkoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. justin.balko@vumc.org.ORCID http://orcid.org/0000-0002-4263-5974
Vanderbilt University Medical Center · USUniversity of California, San Francisco · USMurdoch University · AUThe University of Texas MD Anderson Cancer Center · USUniversity Medical Center Groningen · NLUniversity of California, Los Angeles · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MVanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MTennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Carolyn Audet · 2015 to 2026
$27.5MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6MNATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5MCARDIOVASCULAR SCIENTIST TRAINING PROGRAMT32HL007895 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHIVKUMAR, KALYANAM, WATSON, KAROL E · 1998 to 2023
$9.2MVANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7MTranslational Research in Endocrinology And Diabetes (TREAD)T32DK007061 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Sarah S Jaser, KEVIN D NISWENDER · 1986 to 2026
$8.0MImmunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9MAmerican Heart Association-American Stroke AssociationNCATS NIH HHS UL1 TR002243NCI NIH HHS F30 CA236157NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA217987NCI NIH HHS R01 CA227481NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NHGRI NIH HHS R01 HG010863NHLBI NIH HHS K23 HL138291NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021NHLBI NIH HHS T32 HL007895NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI152183NIAID NIH HHS U01 AI154659NIDDK NIH HHS T32 DK007061NIGMS NIH HHS T32 GM007347NIH HHS S10 OD023475NIH HHS S10 OD025092
Abstract
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy
Indexed as
CD8-Positive T-LymphocytesImmunotherapyMyocarditisVentricular MyosinsAnimalsAutoantigensCTLA-4 AntigenMiceProgrammed Cell Death 1 ReceptorAutoantigensCTLA-4 AntigenPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorVentricular Myosins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.